{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["van Osch TLJ"],"funding":["PPOC grant from Stichting Sanquin bloedvoorziening"],"pagination":["3011-3025"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9828502"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(12)"],"pubmed_abstract":["<h4>Background</h4>The formation of alloantibodies directed against class I human leukocyte antigens (HLA) continues to be a clinically challenging complication after platelet transfusions, which can lead to platelet refractoriness (PR) and occurs in approximately 5%-15% of patients with chronic platelet support. Interestingly, anti-HLA IgG levels in alloimmunized patients do not seem to predict PR, suggesting functional or qualitative differences among anti-HLA IgG. The binding of these alloantibodies to donor platelets can result in rapid clearance after transfusion, presumably via FcγR-mediated phagocytosis and/or complement activation, which both are affected by the IgG-Fc glycosylation.<h4>Objectives</h4>To characterize the Fc glycosylation profile of anti-HLA class I antibodies forme"],"journal":["Journal of thrombosis and haemostasis : JTH"],"pubmed_title":["Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusions."],"pmcid":["PMC9828502"],"funding_grant_id":["2282"],"pubmed_authors":["Geerdes DM","Pongracz T","Vidarsson G","Kerkhoffs JH","de Haas M","Wuhrer M","van Osch TLJ","Kapur R","Mok JY","Porcelijn L","van der Meer PF","Voorberg J","van der Schoot CE","van Esch WJE"],"additional_accession":[]},"is_claimable":false,"name":"Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusions.","description":"<h4>Background</h4>The formation of alloantibodies directed against class I human leukocyte antigens (HLA) continues to be a clinically challenging complication after platelet transfusions, which can lead to platelet refractoriness (PR) and occurs in approximately 5%-15% of patients with chronic platelet support. Interestingly, anti-HLA IgG levels in alloimmunized patients do not seem to predict PR, suggesting functional or qualitative differences among anti-HLA IgG. The binding of these alloantibodies to donor platelets can result in rapid clearance after transfusion, presumably via FcγR-mediated phagocytosis and/or complement activation, which both are affected by the IgG-Fc glycosylation.<h4>Objectives</h4>To characterize the Fc glycosylation profile of anti-HLA class I antibodies forme","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-21T17:58:35.383Z","creation":"2025-04-05T17:02:34.429Z"},"accession":"S-EPMC9828502","cross_references":{"pubmed":["36165642"],"doi":["10.1111/jth.15898"]}}